Skip to main content

Table 1 Baseline demographics and disease characteristics in all randomized subjects

From: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

 

MF-DPI 800 μg QD PM (n = 308)

MF-DPI 400 μg BID (n = 308)

Placebo (n = 295)

Mean age, y

65.3

65.0

65.0

Sex, n (%)

   

   Women

95 (31)

102 (33)

92 (31)

   Men

213 (69)

206 (67)

203 (69)

Race, n (%)

   

   White

271 (88)

264 (86)

252 (85)

   Non-white

37 (12)

44 (14)

43 (15)

Mean body mass index, kg/m2

26.7*

26.1*

27.1

Mean COPD duration, y

7.33*

7.31†

7.26

Pulmonary function

   

   Prebronchodilator FEV1, L

1.32

1.25

1.26

   Postbronchodilator FEV1, L

1.45

1.38

1.41

% FEV1 predicted

   

   Prebronchodilator

43

42

42

   Postbronchodilator

47

46

47

   Reversibility (%)

4

4

5

COPD severity, n (%)‡

   

   FEV1 50%–<80% predicted

97 (32)

88 (29)

81 (28)

   FEV1 30%–<50% predicted

142 (46)

136 (44)

127 (43)

   FEV1 < 30% predicted

60 (20)

67 (22)

67 (23)

   Missing§

8 (3)

17 (6)

20 (7)

  1. BID = twice daily; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; MF-DPI = mometasone furoate administered via a dry powder inhaler.
  2. *n = 305
  3. †n = 306
  4. ‡Sum of % values may not be 100% due to rounding.
  5. §Screen failures or inadequate data (at least one valid measure of prebronchodilator or postbronchodilator FEV1, but not both, were available).
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us